img

Xifaxan® (rifaximin) is a 2-week treatment
for adult patients with irritable bowel syndrome with diarrhea (IBS-D)1,2

Patients can be retreated up to 2 times
if symptoms recur1
img
Xifaxan® (rifaximin) treats IBS-D Differently

Xifaxan is a nonsystemic antibiotic1:

There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering Xifaxan to these patients

Xifaxan works by inhibiting1:

Protein synthesis

The growth of bacteria in the gut

Xifaxan is a 2-week treatment1:

One 550-mg tablet 3 times daily

Patients can be retreated up to 2 times if symptoms recur

IMPORTANT SAFETY INFORMATION - XIFAXAN (rifaximin) 550 mg tablets

XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.

Xifaxan® (rifaximin) is dosed differently

One 550-mg tablet 3 times daily1

2-week (14 days) treatment1

Can be taken with or without food1

Patients can be retreated up to 2 times if symptoms recur1

IMPORTANT SAFETY INFORMATION - XIFAXAN (rifaximin) 550 mg tablets

Clostridium difficile-associated diarrhea (CDAD) has been reported with use of antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.

TRIAL 1 and 2: Proven relief of IBS-D symptoms1

Xifaxan® (rifaximin) patients experienced significant improvements in abdominal pain and stool consistency2

2 Pivotal Trials to Evaluate Efficacy PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE2

Xifaxan patients entered TRIAL 1 and 2 with:

>10 years with IBS-D symptoms2

>80% of days with stool urgency2

Moderate abdominal pain2

At study entry, patients (≥18 years of age) met ROME II Criteria* for IBS1

*Rome II Criteria: At least 12 weeks, which need not be consecutive, in the preceding 12 months of abdominal discomfort or pain that has 2 out of 3 features: 1) Relieved with defecation; and/or 2) Onset associated with a change in frequency of stool; and/or 3) Onset associated with a change in form (appearance) of stool.1

Design of TRIAL 1 and 21

img
img
Randomize 1:1
End of Study
2-week
double-blinded
treatment
10-week post-treatment phase (No study medication)
Primary evaluation period
Xifaxan (n=624)
or placebo (n=634)
3 times daily
img
0
1
2
3
4
5
6
7
8
9
10
11
12
img
img
Primary endpoint:
IBS-D signs
and symptoms
Composite endpoint:
abdominal pain
and stool consistency

Primary endpoint:

The proportion of patients who achieved adequate relief of IBS signs and symptoms for at least 2 of 4 weeks during the month following 14 days of treatment. Adequate relief was defined as a response of “yes or no” to the following weekly Subject Global Assessment (SGA) question: “In regard to your IBS symptoms, compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms?”1

Composite endpoint:

Patients were responders if they experienced both of the following for ≥2 weeks during the month following 2 weeks of treatment1:

A ≥30% decrease from baseline in abdominal pain

A weekly mean stool consistency score <4 (loose stool)

TRIAL 1 AND 2: PROVEN RELIEF
IN IBS-D SYMPTOMS

Significant relief seen in composite endpoint

A composite endpoint of Trial 1 and 2 defined responders by IBS-related abdominal pain and stool consistency measures1

  • Significantly more patients receiving Xifaxan were responders for abdominal pain and stool consistency in Trials 1 and 2, compared with placebo
  • The figure below shows the composite endpoint and individual patient symptoms

Patients were responders if they experienced both of the following for ≥2 weeks during the month following 2 weeks of treatment1:

  • A ≥30% decrease from baseline in abdominal pain
  • A weekly mean stool consistency score <4 (loose stool)

Xifaxan patients experienced
significant IMPROVEMENTS in abdominal pain and stool consistency1,2

TRIAL 1
img
img
80
60
40
20
0
img
% Responders
ABDOMINAL PAIN and
STOOL CONSISTENCY
P<.05
ABDOMINAL PAIN
P=.02
STOOL CONSISTENCY
P=.002
img
img
img
img
img
img
47%
39%
51%
42%
79%
68%
img
Composite Endpoint
img
Xifaxan (n=309)
Placebo (n=314)
TRIAL 2
img
img
80
60
40
20
0
img
% Responders
ABDOMINAL PAIN and
STOOL CONSISTENCY
P<.01
ABDOMINAL PAIN
P=.02
STOOL CONSISTENCY
P=.01
img
img
img
img
img
img
47%
36%
52%
43%
74%
64%
img
Composite Endpoint
img
Xifaxan (n=315)
Placebo (n=320)

XIFAXAN PATIENTS EXPERIENCED SIGNIFICANT RELIEF
of IBS-D symptoms in BOTH PIVOTAL
CLINICAL trials.1

The primary endpoint for both trials was the proportion of patients who achieved adequate relief of IBS signs and symptoms for at least 2 of 4 weeks during the month following 14 days of treatment. Adequate relief was defined as a response of “yes or no” to the following weekly SGA question: “In regard to your IBS symptoms, compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms?”1,2

TRIAL 1 AND TRIAL 2 Primary Endpoint:
Adequate Relief of IBS-D Symptoms1,2

TRIAL 1P=.01
TRIAL 2P=.03
img
img
60
40
20
0
img
% Responders
(n=309)
(n=314)
(n=315)
(n=320)
img
img
img
img
41%
31%
41%
32%
img
Xifaxan
Placebo

TRIAL 1 and 2 most common adverse event1

Adverse
Event
Xifaxan (n=624) Placebo (n=634)
Nausea 3% 2%

IMPORTANT SAFETY INFORMATION - XIFAXAN (rifaximin) 550 mg tablets

There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.

Exercise caution when administrating XIFAXAN concomitantly with a P-glycoprotein (P-gp) inhibitor such as cyclosporine. Concomitant administration of drugs that are P-gp inhibitors can substantially increase the systemic exposure to XIFAXAN. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to XIFAXAN.

Successful repeat treatment withXifaxan® (rifaximin): TRIAL 3 efficacy

TRIAL 3 evaluated repeat treatment in adults with IBS-D meeting Rome III criteria for up to 46 weeks1

  • A total of 2579 patients were enrolled to receive open-label Xifaxan for 14 days
  • Of 2438 evaluable patients, 1074 (44%) responded to initial treatment and were evaluated for continued response or recurrence of IBS-D symptoms
  • A total of 636 patients (59% of responders) had symptom recurrence and were randomized into the double-blind phase of the study
  • These patients were scheduled to receive Xifaxan 3 times daily (n=328) or placebo (n=308) for 2 additional 14-day repeat-treatment courses separated by 10 weeks

TRIAL 3 STUDY DESIGN1

img
img
Open-label
treatment
2438
IBS-D patients
were treated with 2 weeks
of Xifaxan
img
44% (n=1074)
responded§
to Xifaxan treatment
during 4 weeks of follow-up
Responders§ followed up to 18 weeks
for recurrence
No recurrence
Symptom recurrenceǁ
img
36% (n=382)
of open-label
responders did not
experience
recurrence of
symptoms
for up to an 18-week
follow-up period
59% (n=636)
of responders
had a recurrence
Median time to recurrence
was 10 weeks
(range 6 to 24 weeks)
For these patients,
recurrent symptoms
were not as severe
as at baseline
img
Without a recurrence, these patients
did not continue in the trial
Double-blind phase
636
IBS-D patients with recurrent symptoms retreated
with 2 weeks of Xifaxan or placebo
img
328
treated with Xifaxan
308
treated with placebo
ROME III Criteria: Recurrent abdominal pain or discomfort (uncomfortable sensation not described as pain) at least 3 days/month in the last 3 months associated with 2 or more of the following: 1) improvement with defecation; 2) onset associated with a change in frequency of stool; 3) onset associated with a change in form (appearance) of stool.1
§Responders had to experience both of the following during the 4 weeks following treatment:
  • ≥30% improvement from baseline in the weekly average abdominal pain score
  • ≥50% reduction in number of days in a week with mushy or watery stool
llAbdominal pain or mushy/watery stool consistency for 3 weeks of a rolling 4-week period.1

TRIAL 3: DOUBLE-BLIND PHASE

Repeat treatment provided similar symptom relief of abdominal pain and stool consistency1

TRIAL 3 PRIMARY ENDPOINT RESULTS1

img
img
40
20
0
img
% Responders
ABDOMINAL PAIN and
STOOL CONSISTENCY
P<.05
img
img
38%
31%
img
Xifaxan (n=328)
Placebo (n=308)

Primary endpoint responders experienced both a ≥30% improvement from baseline in the weekly average abdominal pain score and a ≥50% reduction in the number of days in a week with mushy or watery stool during the 4 weeks after repeat treatment1

  • Patients achieved the same endpoint after a second course of treatment, having less severe symptoms than at baseline

Patients who experience a recurrence of symptoms can be retreated up to 2 times with the same regimen1

TRIAL 3 most common adverse events1

Adverse
Event
Xifaxan (n=328) Placebo (n=308)
Nausea 2% 1%
ALT increased 2% 1%

IMPORTANT SAFETY INFORMATION - XIFAXAN (rifaximin) 550 mg tablets

XIFAXAN may cause fetal harm. Discontinue in nursing mothers after taking into account the importance of the drug to the mother.

The most common adverse reactions for XIFAXAN in IBS-D were nausea (3%) and increased ALT (2%).

Xifaxan® (rifaximin) has demonstrated a consistenttolerability profile in 3 clinical trials1

TOLERABILITY PROFILE1

Adverse events in ≥2% of patients receiving Xifaxan, at a higher rate than placebo

TRIAL 1 and 2 most common adverse event1
Adverse Event Xifaxan (n=624) Placebo (n=634)
Nausea 3% 2%
TRIAL 3 most common adverse events1
Adverse Event Xifaxan (n=328) Placebo (n=308)
Nausea 2% 1%
ALT increased 2% 1%

Abbreviation: ALT = alanine transaminase

Additional safety information about Xifaxan:

In clinical trials, constipation was observed in 0.5% of Xifaxan patients3

Xifaxan did not cause any clinically relevant antibiotic resistance after 1 to 3 treatment cycles3

  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of antibacterial agents, including Xifaxan, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued

Exercise caution when administrating Xifaxan concomitantly with a P-glycoprotein (P-gp) inhibitor such as cyclosporine1

Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis1

Xifaxan® (rifaximin) Instant Savings Card Most eligible commercially insured patients with coverage for Xifaxan 550 mg will pay no more than $0

Activate a Xifaxan Instant Savings Card

Eligibility Criteria, Terms and Conditions: This offer is only valid for patients with commercial insurance, including commercially insured patients without coverage for Xifaxan. Patients without commercial insurance are not eligible. Commercially insured patients with coverage for Xifaxan will receive savings to reduce their copay to $0. Commercially insured patients without coverage for Xifaxan will receive savings off of retail price to reduce the out-of-pocket cost to as little as $50. The maximum benefit is $1000. Patient is responsible for all additional costs and expenses after application of the maximum benefits. This savings card can be used up to 12 times before the expiration date. This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by Medicaid, Medicare (including Medicare Advantage and Part D Plans), or any other federal or state funded healthcare programs (including VA, DOD, Tricare, CHAMPUS and any state prescription drug programs). This offer is only good in the USA at participating retail pharmacies. This offer cannot be redeemed at other locations, including government-subsidized clinics or facilities. This offer is not valid where otherwise prohibited, taxed, or otherwise restricted. Patient is responsible for reporting receipt of co-pay assistance to any insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. This offer cannot be combined with other offers. This card has no cash value. No other purchase is necessary. This offer is nontransferable. No substitutions are permitted. This card is not health insurance. You understand and agree to comply with the terms and conditions of this offer as set forth above. Offer expires December 31, 2016. Salix Pharmaceuticals reserves the right to rescind, revoke, or amend this offer at any time without notice.

If you have patients who need assistance with their copay for Xifaxan, please direct them to call 1-866-XIFAXAN (943-2926)

img
Pharmacologic class:
Antibiotic
Active
IngRedient:
Rifaximin 550 mg
Indication:
Irritable bowel syndrome with diarrhea (IBS-D) in adults
Adults:
One 550 mg tablet 3 times a day for 14 days. Patients who experience recurrence can be retreated up to two times with the same regimen
Children:
Safety and effectiveness has not been established in patients <18 years
SAFETY
CONSIDERATIONS:
Clostridium difficile-associated diarrhea; evaluate if diarrhea occurs after therapy or does not improve or worsens during therapy. Hepatic impairment; use with caution in patients with severe (Child-Pugh Class C) hepatic impairment due to increased systemic exposure. Concomitant P-glycoprotein inhibitor; caution should be exercised when concomitant use of a P-glycoprotein (P-pg) inhibitor is needed. Pregnancy; may cause fetal harm. Lactation; discontinue in nursing mothers after taking into account the importance of the drug to the mother
Interaction:
Potentiated by P-gp inhibitors (eg, cyclosporine)
Adverse Reactions:
Most common (≥ 2%): ALT increased, nausea
How Supplied:
Tablets—42 pack carton
MPR Monograph © 2016 Haymarket Media, Inc. All rights reserved.
REFERENCES
  1. Xifaxan [prescribing information]. Raleigh, NC: Salix Pharmaceuticals; 2015.
  2. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22—32.
  3. Data on file. Raleigh, NC: Salix Pharmaceuticals; 2015.

XIFI.0100.USA.15

Salix Pharmaceuticals

8510 Colonnade Center Drive, Raleigh, NC 27615

The Xifaxan 550 mg product and the Xifaxan trademark are licensed by Alfa Wassermann S.p.A. to Salix Pharmaceuticals or its affiliates.

This MPR Prescribing Alert is produced as a basic reminder of important information for healthcare professionals. Readers are advised to consult manufacturers and specialists if questions arise about specific products, treatments, or diseases. The publisher and editors do not assume liability for any errors or omissions. MPR and MPR Prescribing Alert are registered trademarks of Haymarket Media, Inc.

© 2016 Haymarket Media, Inc.

Privacy Policy